THE RELATIONSHIP BETWEEN TOCILIZUMAB USE AND EOSINOPHIL COUNT IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RETROSPECTIVE STUDY Romatoid Artritli Hastalarda Tosilizumab Kullanımı ile Eozinofil Sayısı Arasındaki İlişki: Retrospektif Bir Çalışma

Öz

ABSTRACT Objective: This study aimed to determine the relationship between tosilizumab use and eosinophil counts in patients with rheumatoid arthritis. Material and Methods: Thirty five patients diagnosed with rheumatoid arthritis (RA) receiving either synthetic disease-modifying antirheumatic drugs (DMARDs) or tocilizumab treatment were included in this study. Patient age and disease duration, disease activity parameters and eosinophil values were recorded. Results: Comparing the eosinophil counts and percentages of the DMARD group with the Tocilizumab group, any statistically significant differences were found. There was no significant difference in eosinophil counts and percentages in the DMARD group in repeated measurements. However, in the Tocilizumab group, there was a significant difference in both parameters. Conclusion: A significant increase in eosinophil counts was observed in the group receiving tocilizumab therapy at the 1st month. Therefore, during treatment monitoring, especially in the early stages, attention should also be paid to eosinophil values.

Anahtar Kelimeler

• THE RELATIONSHIP BETWEEN TOCILIZUMAB USE AND EOSINOPHIL COUNT IN PATIENTS WITH RHEUMATOID
• ARTHRITIS: A RETROSPECTIVE STUDY
• Romatoid Artritli Hastalarda Tosilizumab Kullanımı ile Eozinofil Sayısı Arasındaki İlişki: Retrospektif Bir Çalışma

THE RELATIONSHIP BETWEEN TOCILIZUMAB USE AND EOSINOPHIL COUNT IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RETROSPECTIVE STUDY Romatoid Artritli Hastalarda Tosilizumab Kullanımı ile Eozinofil Sayısı Arasındaki İlişki: Retrospektif Bir Çalışma

Öz

Objective: This study aimed to determine the relationship between tosilizumab use and eosinophil counts in patients with rheumatoid arthritis. Material and Methods: Thirty five patients diagnosed with rheumatoid arthritis (RA) receiving either synthetic disease-modifying antirheumatic drugs (DMARDs) or tocilizumab treatment were included in this study. Patient age and disease duration, disease activity parameters and eosinophil values were recorded. Results: Comparing the eosinophil counts and percentages of the DMARD group with the Tocilizumab group, any statistically significant differences were found. There was no significant difference in eosinophil counts and percentages in the DMARD group in repeated measurements. However, in the Tocilizumab group, there was a significant difference in both parameters. Conclusion: A significant increase in eosinophil counts was observed in the group receiving tocilizumab therapy at the 1st month. Therefore, during treatment monitoring, especially in the early stages, attention should also be paid to eosinophil values.

Anahtar Kelimeler

• THE RELATIONSHIP BETWEEN TOCILIZUMAB USE AND EOSINOPHIL COUNT IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RETROSPECTIVE STUDY
• Romatoid Artritli Hastalarda Tosilizumab Kullanımı ile Eozinofil Sayısı Arasındaki İlişki: Retrospektif Bir Çalışma
• THE RELATIONSHIP BETWEEN TOCILIZUMAB USE AND EOSINOPHIL COUNT IN PATIENTS WITH RHEUMATOID

Kaynakça

1. 1. Kovalszki A, Weller PF. Eosinophilia. Prim Care. 2016;43(4):607-17.
2. 2. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006;133(5):468-92.
3. 3. Tamaki H, Chatterjee S, Langford CA. Eosinophilia in Rheumatologic/Vascular Disorders. Immunol Allergy Clin North Am. 2015;35(3):453-76.
4. 4. Morrisroe K, Wong M. Drug-induced hypereosinophilia related to tocilizumab therapy for rheumatoid arthritis. Rheumatology (Oxford). 2015;54(11):2113-4.
5. 5. Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H. Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis. Intern Med. 2017;56(12):1585-90.
6. 6. Ikegawa K, Hanaoka M, Ushiki A, Yamamoto H, Kubo K. A caseof organizing pneumonia induced by tocilizumab. Intern Med. 2011;50(19):2191-3.
7. 7. Zuelgaray E, Domont F, Peiffer-Smadja N, Saadoun D, Cacoub P. Tocilizumab-Induced Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in Adult-Onset Still Disease. Ann Intern Med. 2017;167(2):141-2.
8. 8. Imai Y, Kondo Y, Ishigaki S, Nishina N, Ota Y, Hanaoka H, et al. A case of eosinophilic granulomatosis with polyangiitis after prolonged intervals of an anti-interleukin-6 receptor antibody for rheumatoid arthritis. Mod Rheumatol Case Rep. 2022;6(1):83-6.

9. 9. Emmanuel D, Parija SC, Jain A, Misra DP, Kar R, Negi VS. Persistent eosinophilia in rheumatoid arthritis: a prospective observational study. Rheumatol Int. 2019;39(2):245-53.
10. 10. Guellec D, Milin M, Cornec D, Tobon GJ, Marhadour T, Jousse-Joulin S, et al. Eosinophilia predicts poor clinical outcomes in recent-onset arthritis: results from the ESPOIR cohort. RMD Open. 2015;1(1):e000070.